Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 11/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 4/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1412926 | 0.99 | P2RX7 (0.64) | P2RX7ABCB11THRBRIPK1SMYD3 | |
| SCHEMBL1412884 | 0.91 | P2RX7 (0.62) | P2RX7ABCB11THRB | |
| SCHEMBL5390136 | 0.89 | P2RX7 (0.50) | P2RX7ABCB11THRBRIPK1SMYD3 | |
| SCHEMBL1413043 | 0.86 | P2RX7 (0.47) | P2RX7ABCB11THRBRIPK1SMYD3 | |
| SCHEMBL1412889 | 0.85 | P2RX7 (0.69) | P2RX7ABCB11THRB | |
| SCHEMBL1412974 | 0.85 | P2RX7 (0.69) | P2RX7ABCB11THRB | |
| SCHEMBL1412833 | 0.84 | P2RX7 (0.54) | P2RX7ABCB11THRBMEN1KMT2A | |
| SCHEMBL1412963 | 0.80 | P2RX7 (0.49) | P2RX7ABCB11THRB | |
| SCHEMBL1412836 | 0.79 | P2RX7 (0.74) | P2RX7ABCB11 | |
| SCHEMBL5838248 | 0.78 | HSD17B1 (0.50) | P2RX7RIPK1SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214677-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-05-08 | — | — | US | claimed |
| EP-1448535-B1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7235549-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7214677-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20060058302-A1 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. | 2006-03-16 | — | — | US | disclosed |
| EP-1448535-A1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030186981-A1 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003042191-A1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186981-A1 | Benzamide, heteroarylamide and reverse amides | P2RX7, P2RX5, P2RX2 | P2RX7 1/4885ABCB11 866/4885THRB 1200/4885 |
| US-20060058302-A1 | Benzamide, heteroarylamide and reverse amides | P2RX7, P2RX5, P2RX2 | P2RX7 1/4885ABCB11 443/4885THRB 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.